Marietta Investment Partners LLC Has $632,000 Position in Johnson & Johnson (NYSE:JNJ)

Marietta Investment Partners LLC lifted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 14.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,558 shares of the company’s stock after purchasing an additional 450 shares during the period. Marietta Investment Partners LLC’s holdings in Johnson & Johnson were worth $632,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. RE Dickinson Investment Advisors LLC boosted its stake in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after acquiring an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC boosted its stake in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after acquiring an additional 120 shares during the last quarter. Morton Brown Family Wealth LLC boosted its stake in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares during the last quarter. Professional Financial Advisors LLC boosted its stake in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after acquiring an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the second quarter valued at approximately $39,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction that occurred on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 118,795 shares of company stock worth $20,230,174. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Up 0.8 %

Shares of JNJ stock opened at $176.20 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm’s fifty day moving average price is $167.84 and its two-hundred day moving average price is $171.29. The firm has a market capitalization of $460.67 billion, a P/E ratio of 24.54, a PEG ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.60 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson announced that its board has authorized a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 19th. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Barclays began coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Finally, Bank of America reduced their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.